GlaxoSmithKline Pharmaceuticals Q2 Results
- BSE: 500660
- NSE: GLAXO
- ISIN: INE159A01016
- Sector: Biotechnology & Drugs
BSE
2,600
20.40 (0.79%)
20.40 (0.79%)Volume4.07 K
Updated: Fri 7 Aug, 2026 | 15:29:58
NSE
2,599.7020.20 (0.78%)
20.20 (0.78%)Volume34.99 K
Updated: Fri 7 Aug, 2026 | 15:50:09
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Quarter ended Sep 25
Note: Comparison is on QoQ basis
Quarterly - GlaxoSmithKline Pharmaceuticals Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 26 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 661.64 | 658.78 | 16.18% | 705.92 | -6.27% |
| Depreciation/ Amortization | 17.43 | 15.84 | 12.31% | 16.86 | 3.38% |
| Operating Income | 318.30 | 279.66 | 35.06% | 304.85 | 4.41% |
| Net Income | 257.49 | 237.18 | 25.60% | 252.50 | 1.98% |
| Other Operating Expenses Total | 150.63 | 155.96 | 32.49% | 153.86 | -2.10% |
| Net Income Before Taxes | 354.00 | 322.45 | 26.89% | 343.81 | 2.96% |
| Total Revenue | 979.94 | 938.44 | 21.71% | 1,010.77 | -3.05% |
| Selling/ General/ Admin Expenses Total | 138.05 | 159.04 | -9.52% | 150.71 | -8.40% |
| Diluted Normalized EPS | 15.09 | 14.00 | 24.68% | 14.47 | 4.26% |
EQUITY QUICK LINKS
FROM MARKETS
RELATED LINKS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.